Preliminary results from a trial involving 663 participants receiving a mixed schedule of COVID-19 vaccine brands has been released. Participants who had received their first COVID-19 vaccine as AstraZeneca were then offered their second dose as Pfizer at least 8 weeks later.

Higher antibody levels were produced following dose 2 than had been produced following receipt of dose 1. The immune response generated was also stronger compared with a standard 2 dose course of the AstraZeneca COVID-19 vaccine. The side effects reported following a mixed schedule were similar to those experienced by those who received a same brand schedule. This is in contrast to a similar study in the UK which showed higher reports of common side effects following a mixed schedule of COVID-19 vaccination.

To read the article in full refer to the link below:

Nature: Mix-and-match COVID vaccines trigger potent immune response